Session

Mechanisms relevant to therapy resistance in urothelial tumours

Poster Session 82

  • Location:
    Room Vienna (Hall B2, level 0)
  • Chairs:
     R. Nawroth, Munich (DE)
     E. Oosterwijk, Nijmegen (NL)
  • Aims and objectives of this session

    Therapy resistance in prostate cancer develops as a result of activation of multiple signaling pathways. Understanding these mechanisms is a condition for a more efficient therapy. Several abstracts in this session will focus on experimental approaches to combat resistance.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
1042
Association between PDL1 variants and muscle invasive bladder cancer prognosis

By: Masson-Lecomte A.J.A.M.1, Pineda S.2, Rava M.2, Carrato A.3, Tàrdon A.4, Silverman D.5, Rothman N.5, Garcia-Closas M.5, Chanock S.5, Allory Y.6, Real F.X.7, Malats N.2

Institutes: 1Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, 2CNIO, Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, 3Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, 4Oviedo University, Dept. of Preventive Medicine, Oviedo, Spain, 5NCI, Dept. of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services,, Bethesda, Maryland, United States of America, 6Hôpitaux Universitaires Henri Mondor, Dept. of Pathology, Créteil, France, 7CNIO, Dept. of Epithelial Carcinogenesis, Madrid, Spain

1043
Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumour staging in patients undergoing radical cystectomy for bladder cancer

By: Tan Y.G., Eu E., Huang H.H., Lau W.K.O.

Institutes: Singapore General Hospital, Dept. of Urology, Singapore, Singapore

1044
Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with bladder cancer undergoing radical cystectomy

By: Jiménez Marrero P.1, Perez Sanchez M.1, Jorge Pérez N.1, González J.M.2, Kim Lee D.1, Marrero Umpierrez N.1, Hernández Hernández C.1, Hernández Escobar S.1, Marrero Dominguez R.1

Institutes: 1University Hospital of Gran Canaria Dr. Negrín, Dept. of Urology, Las Palmas de Gran Canaria, Spain, 2University Hospital of Gran Canaria Dr. Negrín, Dept. of Research, Las Palmas de Gran Canaria, Spain

1045
EpCAM (epithelial cell adhesion molecule) as the most common target for circulating tumor cells (CTC) identification: Comparison between manual and automated system of isolation and future prospective

By: Busetto G.M.1, Giovannone R.1, Antonini G.1, Gazzaniga P.2, Gentile V.1, De Berardinis E.1

Institutes: 1Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, 2Sapienza Rome University Policlinico Umberto I, Dept. of Molecular Medicine, Rome, Italy

1046
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma

By: Todenhöfer T.1, Kamyabi A.1, Hennenlotter J.2, Seiler R.1, Mcdonald P.3, Moskalev I.1, Stewart C.1, Gao J.1, Bedke J.2, Oo H.Z.1, Fazli L.1, Dedhar S.3, Stenzl A.2, Black P.1

Institutes: 1University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 3British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada

1047
En bloc bipolar resection to optimize TURB samples for organotypic culture and development of targeted treatments in non-muscle invasive bladder cancer

By: Daniel G.1, Roumiguié M.2, Fons P.3, Herbert C.4, Brousset P.1, Mazerolles C.1, Malavaud B.2

Institutes: 1Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, 2Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, 3EVOTEC France, Clinical Translation Group, Toulouse, France, 4EVOTEC France, Dept. of Biology, Toulouse, France

1048
Assessment of the efficacy of repeated instillations of TC-gel mixed with MMC in an invasive rat bladder cancer model

By: Van Valenberg F.J.P.1, Strauss-Ayali D.2, Agmon-Gerstein Y.2, Friedman A.2, Arentsen H.C.1, Witjes J.A.1, Oosterwijk E.1

Institutes: 1Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2UroGen Pharma Ltd., Intravesical Drug Delivery Solutions, Ra’anana, Israel

1049
Benzyl isothiocyanate up-regulates miR-99a-5p and induces autophagy by suppressing mTOR expression

By: Tsai T-F.1, Lin J-F.2, Lin Y-C.1, Chen H-E.1, Chou K-Y.1, Hwang T.I.S.1

Institutes: 1Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, 2Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

1050
Foxp3 interacts with and regulates HIF-1α-VEGF signaling in human bladder cancer

By: Tsai Y-S.1, Kao Y-L.3, Wu K-Y.1, Jou Y-C.2, Chen S-Y.2, Tsai H-T.3, Tzai T-S.3

Institutes: 1National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, 2Christian Chia-Yi Hospital, Dept. of Urology, Chia-Yi, Taiwan, 3National Cheng Kung Hospital, Dept. of Urology, Tainan, Taiwan

1051
Multiple drug induced feedback loops limit the efficacy of PI3K/AKT/mTOR inhibition as a therapy in bladder cancer

By: Sathe A., Wong K.W., Oppolzer I., Von Busch M., Schmid S.C., Seitz A.K., Heck M.M., Gschwend J.E., Retz M., Nawroth R.

Institutes: Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany

1052
Inhibition of cisplatin-induced autophagy enhances apoptotic cell death in human bladder cancer cells

By: Hwang T.1, Lin J-F.2, Lin Y-C.1, Tsai T-F.1, Chen H-E.1, Chou K-Y.1

Institutes: 1Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, 2Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

1053
Endoplasmic reticulum stress as a putative mechanism for attenuated response to intravesical BCG in bladder cancer

By: Lewicki P.1, Liu H.1, O’ Malley P.1, Golombos D.1, Cubillos-Ruiz J.2, Scherr D.1

Institutes: 1Weill Cornell Medical College, Dept. of Urology, New York, United States of America, 2Weill Cornell Medical College, Dept. of Obstetrics and Gynecology, New York, United States of America